CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention
Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy
Giuseppe Patti, MD*,
Massimo Chello, MD*,
Vincenzo Pasceri, MD, PhD, FACC ,
Diego Colonna, MD ,
Annunziata Nusca, MD*,
Marco Miglionico, MD*,
Andrea DAmbrosio, MD*,
Elvio Covino, MD* and
Germano Di Sciascio, MD, FACC*,*
* Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Rome, Italy
Interventional Cardiology Unit, San Filippo Neri Hospital of Rome, Rome, Italy
Second University of Naples, Naples, Italy
Manuscript received May 10, 2006;
revised manuscript received June 19, 2006,
accepted June 26, 2006.
* Reprint requests and correspondence: Dr. Germano Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico University, Via E. Longoni, 83, 00155 Rome, Italy (Email: g.disciascio{at}unicampus.it).
OBJECTIVES: The goal of this work was to investigate whether protection from myocardial injury during percutaneous coronary intervention (PCI) by atorvastatin is related to reduction of endothelial inflammatory response.
BACKGROUND: In the randomized ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial, 7-day pre-treatment with atorvastatin before PCI significantly reduced procedural myocardial injury; mechanisms underlying this effect are not characterized.
METHODS: In a planned subanalysis of the ARMYDA trial, a subgroup of 76 patients was blind-tested for measurement of plasma levels of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin: 38 patients belonged to atorvastatin (40 mg/day) and 38 to the placebo arm. Adhesion molecules were evaluated 7 days before intervention, immediately before PCI, and after 8 and 24 h.
RESULTS: Reduction of procedural myocardial injury after statin pre-treatment was also confirmed in this subgroup. Intercellular cell adhesion molecule-1, E-selectin, and VCAM-1 levels were not different at randomization and before intervention in either arm. At 8 h, increase of ICAM-1 levels was similar in the 2 arms, whereas 24-h levels were significantly lower in the atorvastatin versus placebo group (282 ± 56 vs. 325 ± 70 ng/ml; p = 0.007). Attenuation of E-selectin elevation occurred at 8 h in the atorvastatin group (50 ± 8 vs. 59 ± 13 ng/ml; p = 0.002) and became even more significant at 24 h (57 ± 9 vs. 73 ± 18 ng/ml; p = 0.0008). Vascular cell adhesion molecule-1 levels were not different at any time point in the 2 arms.
CONCLUSIONS: In patients undergoing PCI, reduction of procedural myocardial injury after 7-day pre-treatment with atorvastatin is paralleled by concomitant attenuation of post-procedural increase of ICAM-1 and E-selectin levels; thus, reduction of endothelial inflammatory response may explain this protective effect of statins.
|
Abbreviations and Acronyms
| | ARMYDA = Atorvastatin for Reduction of MYocardial Damage during Angioplasty | | ARMYDA-CAMs = Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules substudy | | CRP = C-reactive protein | | ICAM-1 = intercellular cell adhesion molecule-1 | | VCAM-1 = vascular cell adhesion molecule-1 |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2006 48: A39-A40.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. Patti, C. P. Cannon, S. A. Murphy, S. Mega, V. Pasceri, C. Briguori, A. Colombo, K. H. Yun, M. H. Jeong, J.-S. Kim, et al.
Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies
Circulation,
April 19, 2011;
123(15):
1622 - 1632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Di Sciascio, G. Patti, V. Pasceri, L. Gatto, G. Colonna, A. Montinaro, and on behalf of the ARMYDA-5 PRELOAD Investigators
Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Randomized Trial
J. Am. Coll. Cardiol.,
August 10, 2010;
56(7):
550 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tsimikas
High-Dose Statins Prior to Percutaneous Coronary Intervention: A Paradigm Shift to Influence Clinical Outcomes in the Cardiac Catheterization Laboratory
J. Am. Coll. Cardiol.,
December 1, 2009;
54(23):
2164 - 2166.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Heusch, P. Kleinbongard, D. Bose, B. Levkau, M. Haude, R. Schulz, and R. Erbel
Coronary Microembolization: From Bedside to Bench and Back to Bedside
Circulation,
November 3, 2009;
120(18):
1822 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Ellis and S. Anwaruddin
Recapturing the Magic: Revisiting the Pleiotropic Effects of Statins in Percutaneous Coronary Revascularization
J. Am. Coll. Cardiol.,
August 4, 2009;
54(6):
566 - 568.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, and A. Montinaro
Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial
J. Am. Coll. Cardiol.,
August 4, 2009;
54(6):
558 - 565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1128 - 1133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nusca, R. Melfi, and G. Di Sciascio
Review: Percutaneous coronary interventions and statins therapy
Therapeutic Advances in Cardiovascular Disease,
April 1, 2008;
2(2):
101 - 107.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, A. Montinaro, and G. Di Sciascio
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1272 - 1278.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|